Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + oxaliplatin + sulfur hexafluoride microbubbles
- Development stage
- Unknown
- Lead developer
- Peking University Cancer Hospital & Institute
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
This experimental therapeutic approach, being investigated by Peking University Cancer Hospital & Institute (NCT02233205), combines standard-of-care chemotherapy with ultrasound-stimulated microbubbles to treat liver metastases from gastrointestinal tumors and pancreatic carcinoma. The regimen typically involves gemcitabine or a platinum-based agent (such as oxaliplatin) administered alongside SonoVue (sulfur hexafluoride microbubbles). The core mechanism is sonoporation: the application of ultrasound causes the microbubbles to oscillate and burst, creating temporary pores in the vascular endothelium and tumor cell membranes. This physical disruption enhances the extravasation and intracellular uptake of the chemotherapy drugs, potentially overcoming resistance and increasing local drug concentration within the tumor. It is primarily targeted at patients who have failed routine chemotherapy.
- Brand names
- SonoVue
- Other names
- Ultrasound Microbubbles and Chemotherapyplatinum and gemcitabineultrasonic microbubbles
02
Targets
DNADNA polymerase familyRNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on gemcitabine + oxaliplatin + sulfur hexafluoride microbubbles.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + oxaliplatin + sulfur hexafluoride microbubbles.